Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Parallel-Group, Double-Blind, Multicenter Study Investigating the Safety and Efficacy of NT 201 Compared With Placebo in Adult Participants With Moderate to Severe Platysma Prominence in the United States

NCT07122193 is registered in ClinicalTrials.gov with Merz North America, Inc. as lead sponsor.

NCT NCT07122193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07122193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Parallel-Group, Double-Blind, Multicenter Study Investigating the Safety and Efficacy of NT 201 Compared With Placebo in Adult Participants With Moderate to Severe Platysma Prominence in the United States
Lead sponsor
Merz North America, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 27, 2025
Completion date
September 30, 2027
Enrollment
300 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

acetylcholine release inhibitors, botulinum toxins, type a, cholinergic agents, incobotulinumtoxina, membrane transport modulators, molecular mechanisms of pharmacological action, neuromuscular agents, neurotransmitter agents, peripheral nervous system agents, physiological effects of drugs